Sg. Myerson et al., Left ventricular hypertrophy with exercise and ACE gene insertion/deletionpolymorphism - A randomized controlled trial with losartan, CIRCULATION, 103(2), 2001, pp. 226-230
Citations number
43
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-Local cardiac renin-angiotensin systems may regulate left ventri
cular (LV) hypertrophic responses. The absence (deletion [D]) of a 287-bp m
arker in the ACE gene is associated with greater myocardial ACE levels and
exercise-related LV growth than is its presence (insertion [I]), an effect
potentially mediated through either increased activity of the cellular grow
th factor angiotensin II on the angiotensin type 1 (AT(I)) receptor or incr
eased degradation of growth-inhibiting kinins, We sought to confirm ACE gen
otype-associated exertional LV growth and to clarify the role of the AT, re
ceptor in this association.
Methods and Results-One hundred forty-one British Army recruits homozygous
for the ACE gene (79 DD and 62 II) were randomized to receive losartan (25
mg/d, a subhypotensive dose inhibiting tissue AT, receptors) or placebo thr
oughout a 10-week physical training program. LV mass, determined by cardiac
magnetic resonance, increased with training (8.4 g, P<0.0001 overall; 12.1
versus 4.8 g for DD versus II genotype in the placebo limb, P=0.022), LV g
rowth was similar in the losartan arm: 11.0 versus 3.7 g for DD versus II g
enotypes (P=0.034), When indexed to lean body mass, LV growth in the II sub
jects was abolished, whereas it remained in the DD subjects (-0.022 versus
0.131 g/kg, respectively; P=0.0009).
Conclusions-ACE genotype dependence of exercise-induced LV hypertrophy is c
onfirmed. Additionally, LV growth in DD (unlike II) subjects is in excess o
f the increase in lean body mass. These effects are not influenced by AT, r
eceptor antagonism with the use of losartan (25 mg/d), The 2.4-fold greater
LV growth in DD men may be due to the effects of angiotensin II on other r
eceptors leg, angiotensin type 4) or lower degradation of growth-inhibitory
kinins.